GlassScriptPhysician profile
David Donnell Perz
NPI 1558450684
$10,006.54
in general payments reported to CMS, 2019-2025
45 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2020: $457 · 2021: $858 · 2022: $2,694 · 2023: $1,598 · 2024: $1,482 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,726.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,961.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $846.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $680.61 | 2020-2025 | |
| Corcept Therapeutics | $675.61 | 2022-2025 | Korlym |
| Amgen INC. | $573.59 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $479.12 | 2019-2024 | Spravato, Xarelto |
| Allergan, INC. | $434.14 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.46 | 2019-2025 | Xifaxan |
| Recordati_rare_diseases_inc. | $369.93 | 2024-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $338.33 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $281.08 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $269.62 | 2023-2025 | |
| Pfizer INC. | $247.57 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.53 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $226.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $198.35 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.44 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $175.06 | 2020-2025 | Ozempic, Rybelsus |
| Lundbeck LLC | $157.76 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $138.59 | 2019-2024 | |
| Lilly USA, LLC | $114.48 | 2019-2023 | Mounjaro |
| Nevro Corp. | $114.33 | 2023 | Senza |
| Amarin Pharma, INC. | $103.89 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $95.87 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $80.10 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Arbor Pharmaceuticals, INC. | $74.53 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $64.79 | 2019-2023 | Belbuca |
| Abbott Laboratories | $54.26 | 2022-2025 | Freestyle Libre 3 |
| Strongbridge US INC. | $52.03 | 2019-2020 | |
| Gilead Sciences, INC. | $45.82 | 2023 | |
| Scilex Pharmaceuticals INC. | $31.42 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $30.91 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $29.51 | 2023 | Aptima |
| Indivior INC. | $28.91 | 2019-2020 | |
| Exact Sciences Corporation | $27.72 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $25.54 | 2025 | Camzyos |
| Baxter Healthcare | $21.19 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Seqirus USA INC | $18.07 | 2022 | |
| Halozyme INC | $17.52 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $17.13 | 2022 | |
| Eisai INC. | $17.11 | 2025 | |
| Esperion Therapeutics, INC. | $17.11 | 2025 | Nexletol |
| Sumitomo Pharma America, INC. | $16.39 | 2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $12.97 | 2019 | |
| Philips North America LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Perz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.